Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length-Reference-Cited by-同舟云学术

Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length

Published:2021-11-10 Issue: Volume: Page:
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Cocchiara Francesco,Campana Claudia,Nista Federica,Corica Giuliana,Ceraudo Marco,Milioto Angelo,Criminelli Rossi Diego,Zona Gianluigi,Ferone Diego,Gatto Federico^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s11102-021-01193-w.pdf

Reference36 articles.

1. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest. https://doi.org/10.1172/JCI39375

2. Burton T, Le Nestour E, Neary M, Ludlam WH (2016) Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. https://doi.org/10.1007/s11102-015-0701-2

3. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, Dekkers OM, Sorensen HT, Jorgensen JO (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. https://doi.org/10.1530/EJE-16-0117

4. Gatto F, Trifiro G, Lapi F, Cocchiara F, Campana C, Dell’Aquila C, Ferrajolo C, Arvigo M, Cricelli C, Giusti M, Ferone D (2018) Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine. https://doi.org/10.1007/s12020-018-1630-4

5. Caputo M, Ucciero A, Mele C, De Marchi L, Magnani C, Cena T, Marzullo P, Barone-Adesi F, Aimaretti G (2019) Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region. Italy J Endocrinol Invest. https://doi.org/10.1007/s40618-018-0928-7

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion;European Journal of Endocrinology;2024-05-21

3. Investigational drugs for the treatment of acromegaly: new agents to transform therapy;Expert Opinion on Investigational Drugs;2024-04-30

4. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs;Journal of Endocrinological Investigation;2023-09-11

5. The socioeconomic burden of acromegaly;European Journal of Endocrinology;2023-08